Heterogeneous induction of apoptosis in colon cancer cells by wild-type p53 gene transfection.

Namoto, Masaaki; Yonemitsu, Yoshikazu; Nakagawa, Kei; Hashimoto, Shuichi; Kaneda, Yasufumi; Nawata, Hajime; Sueishi, Katsuo

doi:10.3892/ijo.12.4.777

Cited by 4 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Formulation modi® cation-related eOE ects include docking of lipoplexes on to larger solid particles such as polystyrene divinylbenzene microspheres , inclusion of fusogenic viral coat proteins (Namoto et al 1998), or the presence of other non-lipidic biomolecules in the precomplexed liposomes (Chen et al 2000). Complex-related eOE ects include the time lipoplexes are allowed to mature before addition to cells (Yang & Huang 1998), DNA to liposome ratio (Bergan et al 2000), and size of the lipoplexes (Jaaskelainen et al 2000).…”

Section: Factors Affecting Lipoplex-mediated Gene Transfermentioning

confidence: 99%

Cytotoxicity issues pertinent to lipoplex-mediated gene therapy in-vivo

Dass

2002

Journal of Pharmacy and Pharmacology

View full text Add to dashboard Cite

Cationic liposomes bind with nucleic acids such as plasmids and oligodeoxynucleotides to form complexes known as lipoplexes. Although these lipoplexes have several advantages over other forms of nucleic acid transfer methods in cell culture and in-vivo, toxicity remains a problem, especially in-vivo. Nevertheless, these carriers have been used in clinical trials against cystic brosis and cancer and their usage is attributed mainly to their versatility, especially when it comes to the range of routes available for administration of nucleic-acid-based drugs in-vivo.

show abstract

Section: Factors Affecting Lipoplex-mediated Gene Transfermentioning

confidence: 99%

Cytotoxicity issues pertinent to lipoplex-mediated gene therapy in-vivo

Dass

2002

Journal of Pharmacy and Pharmacology

View full text Add to dashboard Cite

show abstract

“…Because of their positively charged lipids, they bind to the anionic DNA molecules, creating stable complexes that can be injected in living organisms. This non-viral delivery system has been used to introduce p53 into various tumours [56][57][58][59], and -as is the case with viral vectors -the effect of the liposomes is enhanced when they are used in combination with other therapies (chemo-or radio-) [60]. The systemic intravenous administration of p53 by cationic liposomes affects tumour growth and metastases of breast cancer cells injected into nude mice [56].…”

Section: Gene Replacement Therapymentioning

confidence: 99%

Targeting p53 in Cancer

Chêne

2001

CMCACA

View full text Add to dashboard Cite

The loss of p53 function is a very important event in cancer. The absence of a functional p53 in tumours favours cancer development, and it has been suggested that it also influences the efficacy of both chemotherapy and radiotherapy. The p53 pathway is therefore the subject of intense research, both in academia and in industry, to identify new compounds targeting tumours with an altered p53. Different strategies are currently under investigation. They can be divided into two groups: biological and chemical strategies. The biological strategies utilise the immune system to eliminate the tumours overexpressing p53 mutants. Alternatively they use vectors delivering a functional p53 gene in tumours or engineered viruses, which selectively target p53-defective cells. The chemical strategies are based on the design of compounds that stabilise or activate the p53 mutant proteins, inhibit the interaction between p53 and hdm2, or act on the p53-binding chaperone proteins. In this review, the current progress in these different approaches will be analysed.

show abstract

Particle-Mediated Intravascular Delivery of Oligonucleotides to Tumors: Associated Biology and Lessons from Genotherapy

Dass

2001

Drug Delivery

View full text Add to dashboard Cite

For a solid tumor to become life-threatening, an adequate blood supply has to be established. Although neovascularization has dire consequences for the host, it furnishes a common route through which tumors may be accessed and eradicated by drugs. The fact that a tumor's vasculature is relatively more permeable than that of healthy host tissue means selective delivery of drugs may be achieved. The role played by the cells making up the tumor vascular bed, vascular endothelial cells (VECs), has to be evaluated closely in attempts to design ways for enhancing drug delivery to solid tumors via the vasculature. The two major roles of VECs in the body, as barrier and as transport, are both highly pertinent to drug delivery. Our review examines how VECs may be manipulated in vivo to improve the selective delivery of carriers for oligonucleotide constructs to solid tumors. It also discusses how oligonucleotide drugs may be targeted against tumor VECs on the premise that by killing these cells, the tumor itself will perish. Cationic liposomes and microspheres are the major delivery vehicles discussed, with added analyses of such other nucleic acid carriers as nanospheres, dendrimers, and polyethyleneimine.

show abstract

Heterogeneous induction of apoptosis in colon cancer cells by wild-type p53 gene transfection.

Cited by 4 publications

References 0 publications

Cytotoxicity issues pertinent to lipoplex-mediated gene therapy in-vivo

Cytotoxicity issues pertinent to lipoplex-mediated gene therapy in-vivo

Targeting p53 in Cancer

Particle-Mediated Intravascular Delivery of Oligonucleotides to Tumors: Associated Biology and Lessons from Genotherapy

Contact Info

Product

Resources

About